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were women. The control group was selected to show an optimal comparability in 
terms of demographic and morbidity measures between the two groups. The inter-
vention group showed better compliance (87.9% vs. 71.4%, p= 0.001). BP control was 
52.5 vs. 53.1% (p= NS) initially and 63.2% vs. 55.6% at the end of the study (p< 0.001) 
for the intervention group vs. control, respectively. The follow-up average cost per 
patient and year was € 377.9 vs. € 442.4, p< 0.001 (reduction in intervention group: 
66 € ). 82% of health care professionals and 91% of patients were satisfied with 
the DMP. ConClusions: The DMP has improved adherence to treatment and BP 
control and has reduced health care management costs. If the study results were 
extrapolated to the overall population of Badalona, a potential saving of 1.7 million 
per year would be achieved.
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objeCtives: Venous thromboembolism (VTE) is a common cardiovascular condition, 
frequently leading to severe complications and requiring high-cost health care interven-
tions. New oral anticoagulants (nOACs) have demonstrated to be efficacious and safe 
in VTE prevention of patients undergoing total hip replacement (THR) and total knee 
replacement (TKR). This analysis is aimed present article aims to evaluate its economic 
impact in the perspective of the Italian SSN. Methods: We conducted a budget impact 
analysis to estimate clinical outcomes and economic consequences associated to the 
reimbursement of apixaban in the prevention of VTE as a consequence of major ortho-
pedic surgery, over a three-year time horizon. The analysis compared two alternative sce-
narios, with apixaban either reimbursed (Scenario B) or not reimbursed (Scenario A) by 
the Italian SSN. Only direct health care costs have been considered. Results: According 
to market assumptions, it is estimated that 1.2%, 3.7%, and 6.5% of THR patients, and 
1.2%, 3.8% and 6.7% of TKR patients, would be treated with apixaban over the first three 
years since launch. The introduction of apixaban, at the estimated daily cost of € 2.48/
die, would translate into a budget impact of € 14.3 mln, € 45.5 mln, and € 81.4 mln at years 
1, 2 and 3 since launch, respectively. This expenditure would be more than offset by sav-
ings, due to: i) reduction of prescriptions of alternative treatment options (other nOACs, 
low-molecular weight heparins, fondaparinux); ii) reduction of the economic burden 
attributable of CV complications of VTE. Finally, Scenario B resulted slightly favourable 
compared to Scenario A, leading to economic savings for about € 50 thousands over 
three years. ConClusions: Reimbursement of apixaban does not determine a budget 
impact increase for Italian SSN, and offers an additional option to prevent high-cost 
event provoked by VTE. Its usage may be considered fully sustainable from a pharmaco-
economic viewpoint.
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objeCtives: Heart failure places a significant burden on the resources of the NHS. 
The aim of this study was to compare from a budgetary perspective the current treat-
ment of patients with heart failure and left ventricular dysfunction with an estimate 
of what could be achieved if the use of evidence-based medicine was optimised in 
accordance with national guidance. Methods: Quality and Outcomes Framework 
prevalence and Hospital Episode Statistics data 2011/12 were analysed to determine 
the number of hospital admissions associated with patients with a diagnosis of heart 
failure for each Clinical Commissioning Group (CCG) and GP Practice in England. These 
data were adjusted for patients with left ventricular dysfunction who were in sinus 
rhythm and hospitalisation costs were applied. This was combined with the cost 
associated with the current use of evidence-based medicine to determine the total 
cost associated with this condition. This was compared with an estimate of total costs 
(hospitalisation and medication) if patients received the levels of evidence-based 
therapy, and outcomes, reported in the SHIFT trial. SHIFT was chosen as the largest 
and most recent contemporary trial in heart failure and left ventricular dysfunction, 
which reflects the optimal use of recommended therapies. Data for each CCG and 
GP practice in England is available via a model presented in Microsoft excel® or 
Apple numbers®. Results: Increasing the use of evidence-based therapy to the 
levels achieved in the SHIFT trial can potentially release estimated funding of up to 
£175m for the population of England, £810,000 for a CCG with a population of 250,000 
and £32,000 for a GP practice with a list size of 10,000. ConClusions: If the use of 
evidence-based therapy for patient’s heart failure and left-ventricular dysfunction is 
increased from current levels, significant improvements in terms of patient outcomes 
and the use of NHS funding can be achieved.
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objeCtives: Drug Eluting Balloon (DEB) is a promising alternative for the treat-
ment of patients with peripheral arterial disease, due to the potential reduction 
in re-intervention rates and cost-savings compared to other technologies com-
monly used. The objective of this analysis was to assess the economic impact of 
DEB and other endovascular therapies for patients with femoral-popliteal dis-
ease. Methods: A budget impact model was developed to compare the relative 
impact in Italy of four different index procedure treatments (PTA with regular bal-
loons, DEB, bare metal stents (BMS) and drug eluting stents (DES)) based on the 
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objeCtives: Electronic Patient Record has proven useful to assess the benefits, 
harms and costs in the real world. To describe the association between the use 
of statins and cardiovascular events in patients with myocardial ischemia by 
means an Electronic Patient Record (ePR) as the basis for a retrospective cohort 
study. Methods: To evaluate the association between the use of statins and car-
diovascular events, we conducted a cross-sectional study with patients in the ePR 
of the Heart Institute (InCor) - University of São Paulo Medical School. Patients were 
considered for the period between 2004 and 2012 and evaluated in terms of the 
association between the use of statins with prevalence of percutaneous coronary 
intervention (PCI), coronary artery bypass graft (CABG) and inpatient mortality. A 
total of 46,757 patients were randomly selected and matched for gender, age group 
(18-49/50-59/60-69/> 70), and category of cardiovascular disease diagnosis, being 
from three ICD-10 groupings, I20-I25/I63-I69/G45/I70. The pairing resulted in two 
groups, each of them with 14,654 patients, a group with prescription of statin (SG) 
and a group for comparison (CG) without statin. Results: A total of 67.4% of the 
patients registered in the ePR used statins. The presence of reverse causality, very 
common in cross-sectional studies, was observed in patients submitted to revascu-
larization procedures. Revascularization was made present in 14% of CG versus 42% 
of SG, which is justified by the drug administration for care of patients undergoing 
those procedures. Mortality was 5.8% in CG and 4.7% in SG, with prevalence rates 
of 80%. The absolute reduction in the prevalence of death between groups was 
1.1% (95%CI:0,6-1,6%) in favor of the use of statins. ConClusions: Statins were not 
prescribed to approximately one third of the patients, the use of statins was higher 
in patients undergoing revascularization procedures and, was also associated with 
a 20% reduction in the occurrence of mortality.
CardIoVasCular dIsorders – Cost studies
PCV35
Budget ImPaCt analysIs of routIne gentamICIn-Collagen ImPlants 
for the PreVentIon of surgICal sIte InfeCtIon (ssI) In hIgh rIsk 
CardIothoraCIC surgery PatIents
Satherley A.W.1, Sayers J.2, Fitzsimons E.2
1GfK Bridgehead, Melton Mowbray, UK, 2EUSA Pharma, Stevenage, UK
objeCtives: The SSI rate after cardiothoracic surgery is estimated at 7.3% by the 
UK Health Protection Agency (HPA) for high risk patients. This represents a burden 
on resources, through greater risk of in-hospital mortality and increased length 
of hospital stay (mean 22.1 extra days for deep SSI). Treatment guidelines recom-
mend IV antibiotic prophylaxis before surgery; however a challenge in high-BMI 
and diabetic patients (high risk) is the inability of systemic antibiotics to suffi-
ciently penetrate target tissue. It is however estimated that 40%-60% of SSIs are 
avoidable, with clinical data supporting additional use of local gentamicin-collagen 
for SSI prevention. The purpose of this study was to examine the budget impact 
case from a UK NHS perspective of routinely administering gentamicin-collagen 
local prophylaxis against SSI in high risk patients undergoing cardiothoracic sur-
gery. Methods: A literature review was undertaken regarding gentamicin-collagen 
efficacy in reducing SSI in cardiothoracic patients, NHS costs of SSI, and annual UK 
cardiothoracic patient numbers. The SSI rate in cardiothoracic surgery was obtained 
from HPA data. Findings were incorporated into a decision tree budget impact model 
to analyse potential savings from routine use of gentamicin-collagen in high risk 
cardiothoracic patients. Results: Considering a cohort of 3710 high-risk cardio-
thoracic patients, annual NHS costs of SSI are £2,164,316. Administration of two 
gentamicin-collagen implants to each high risk patient would cost £200 per patient. 
Assuming a 59% reduction in SSI; this would prevent 197 sternal wound infections, 
with direct savings of £1,590,882 per year, a net saving of £229 per cardiothoracic 
surgery patient. ConClusions: Significant NHS and hospital trust savings may 
be achievable through routine use of gentamicin-collagen implants in high risk 
cardiothoracic surgery patients. A conservative estimate of high-risk patient num-
bers was used in the analysis, suggesting the scope for budgetary savings could 
exceed reported findings.
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objeCtives: To evaluate effectiveness of an interventional strategy (disease man-
agement program (DMP)) supported by a telemedicine platform in patients with 
mild/moderate hypertension. Methods: Quasi-experimental design, paired data 
with control group (1:2, patients were matched by age and gender). Study pop-
ulation and follow-up period: patients from 6 primary care centers in Badalona 
(Barcelona, Spain) were followed-up during 2011 and 2012. Study groups: interven-
tion group (telemedicine program) and control group (usual clinical practice). The 
intervention consisted on establishing a permanent channel of interaction with 
the patient (telemedicine platform) and providing the patient with educational 
materials, clinical monitoring, SMS, phone calls, etc. Main measures: Demographic, 
co-morbidity, anthropometric and biochemical parameters, adherence to treat-
ment, blood pressure control (BP: 140/90 mmHg), associated health care man-
agement costs and satisfaction surveys to professionals and patients. Statistical 
significance:p< 0.05. Results: A total of 750 patients were included (intervention 
group n= 250, control group n= 500). Mean age was of 64.2 years old 52.1% of patients 
